论文部分内容阅读
目的探讨在新生儿重症肺炎及其并发症的治疗中使用静脉用丙种球蛋白(IVIG)的临床效果。方法选取2012年5月~2014年5月我院收治的160例新生儿重症肺炎患儿的临床资料进行回顾性分析,依据是否给予IVIG治疗分为IVIG组(81例)与对照组(79例)。比较两组患儿的临床疗效、呼吸困难缓解时间、住院时间、机械通气时间及并发症的发生情况。结果与对照组比较,IVIG组患儿的呼吸困难缓解时间、住院时间及机械通气时间均显著缩短,有效率明显升高,差异有统计学意义(P<0.05)。与对照组比较,观察组患儿胸腔积液和肺不张的发生率显著降低,差异有统计学意义(P<0.05);两组患儿呼吸衰竭、肝功能损害的发生率比较,差异无统计学意义(P>0.05)。结论 IVIG辅助治疗新生儿重症肺炎效果确切,且能减少并发症。
Objective To investigate the clinical effect of intravenous gamma globulin (IVIG) in the treatment of severe neonatal pneumonia and its complications. Methods The clinical data of 160 neonates with severe pneumonia treated in our hospital from May 2012 to May 2014 were retrospectively analyzed. According to whether IVIG treatment was given or not, the patients were divided into IVIG group (81 cases) and control group (79 cases ). The clinical curative effect, respiratory distress time, hospitalization time, mechanical ventilation time and complication of the two groups were compared. Results Compared with the control group, the time of remission, hospital stay and duration of mechanical ventilation were significantly shortened and the effective rate was significantly increased in the IVIG group (P <0.05). Compared with the control group, the incidence of pleural effusion and atelectasis in the observation group was significantly lower (P <0.05); the incidence of respiratory failure and hepatic dysfunction in the two groups were significantly different Statistical significance (P> 0.05). Conclusion IVIG adjuvant treatment of neonatal severe pneumonia is effective and can reduce the complications.